So, QuidelOrtho Corp (QDEL) had a rough Wednesday. The diagnostic healthcare products maker released its preliminary first-quarter 2026 revenue numbers, and let's just say investors weren't thrilled. The stock tanked to a new 52-week low, down over 32%. Ouch.

Weak Flu Season, China Snags Weigh On Q1 Sales

Here's the headline number: preliminary unaudited revenue in the range of $615 million to $620 million for the first quarter. The consensus estimate was sitting at $680.59 million. That's a miss, and not a small one.

Why the shortfall? The company points to a weaker respiratory season—U.S. Influenza-like Illness visits were down about 30% compared to last year. Then there are the international headaches: slower sales through distributors in China and delays in certain orders from the EMEA region (that's Europe, the Middle East, and Africa).

On top of the revenue miss, the San Diego-based company expects free cash flow to be negative in the first half of 2026. For the first quarter specifically, they're projecting free cash flow in the range of $(65) million to $(70) million. The silver lining? They still think full-year 2026 free cash flow will be positive. But right now, the cash isn't flowing in the right direction.

Analyst Flags Execution Risks Despite Management Confidence

Management, according to William Blair, still believes hitting the low end of its full-year guidance is achievable after this update. But analyst Andrew Brackmann expects investors to remain, well, skeptical.

Reaching that low end depends on a few things going right: a typical fourth-quarter respiratory season (after a weak start), no meaningful reimbursement changes in China (where visibility is limited), and a normalization in the Middle East. That region accounts for 3%–4% of sales and hasn't shown improvement yet, despite a ceasefire. That's a lot of "ifs."

China Uncertainty And Segment Weakness Cloud Outlook

William Blair expects estimates to fall below the guidance range, especially given the ongoing uncertainty in China. Here's the kicker: China is a high-margin segment. Any disruption there doesn't just ding sales; it has an outsized impact on earnings.

While the first-quarter miss was largely driven by factors outside management's control (like the flu, or lack thereof), the analyst believes investors are now zooming out to look at the broader risk picture.

The core business—about 70% of revenue—is described as solid. But weakness in the remaining 30% is dragging down the overall financial performance. Add in elevated debt levels and that limited near-term free cash flow, and you've got a recipe for investor anxiety.

The stock's steep decline reflects continued concern around the China business, where management has limited control. And then there's the specter of potential reimbursement changes in China. The timing and financial impact of those are unclear, which is basically Wall Street's version of a haunted house.

QDEL Price Action: QuidelOrtho shares were down 32.13% at $11.87 at the time of publication on Thursday. The stock is trading at a new 52-week low.